is an organic compound
with the formula
N. The molecule is one of the three isomeric amines
. It is used primarily as a research tool and is helpful in characterizing subtypes of potassium channel
4-Aminopyridine is prepared by the decarbonylation of pyridine-4-carboxyamide.
It has been used clinically in Lambert-Eaton myasthenic syndrome
and multiple sclerosis
because by blocking potassium channels it prolongs action potentials
thereby increasing transmitter release at the neuromuscular junction
and elsewhere. The drug Pinacidil is a derivative of 4-aminopyridine that is also used as a potassium channel opener.
The drug, known as Neurelan, has been shown to reverse tetrodotoxin toxicity in animal experiments.
It is also marketed as Fampridine by Acorda for the treatment of multiple sclerosis, for which it is now in Phase III clinical trials.
4-Aminopyridine is marketed as an avicide under the trade name Avitrol. In this treatment it causes convulsions and rarely death, depending on dosage.
4-Aminopyridine (4-AP) is a drug shown to improve visual function and motor skills and relieve fatigue in patients with Multiple Sclerosis
(MS). 4-AP is most effective in patients with the chronic progressive form of MS, in patients who are temperature sensitive, and in patients who have had MS for longer than three years. Common side effects include dizziness, nervousness and nausea, and the incidence of adverse effects was shown to be less than 5% in all studies.
4-AP works as a potassium channel blocker. Electrophysiologic studies of demyelinated axons show that abnormal potassium currents decrease action potential duration and amplitude and contribute to conduction failure. Potassium channel blockade prolongs the depolarization phase of the action potential, increasing conductivity along the demyelinated axon.
MS patients treated with 4-AP exhibited a response rate of 29.5% to 80%. A long-term study (32 months) indicated that 80-90% of patients who initially responded to 4-AP exhibited long-term benefits. Although improving symptoms, 4-AP does not inhibit progression of MS.
Spinal cord injury patients have also seen improvement with 4-AP therapy. These improvements include sensory, motor and pulmonary function, with a decrease in spasticity and pain..
Conditions associated with overdose have included parasthesias
., and atrial fibrillation